Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin

Cancer

Volumn 98, Issue 7, 2003, Pages 1514-1520

  Wun, Ted ^a,b,c   Law, Lisa ^a   Harvey, Danielle ^a   Sieracki, Barbara ^a   Scudder, Sidney A ^a   Ryu, Janice K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Erythropoietin; Thromboembolism; Tumor hypoxia; Uterine cervix

Indexed keywords

CISPLATIN; FLUOROURACIL; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; WARFARIN;

ADULT; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; FEMALE; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; HYDRONEPHROSIS; HYPOXIA; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; NEPHROTOXICITY; PATIENT SELECTION; PELVIS SURGERY; PHLEBOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; TREATMENT OUTCOME; UREMIA; UTERINE CERVIX CARCINOMA; VAGINA CANCER; VEIN THROMBOSIS;

ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS; VENOUS THROMBOSIS;

EID: 0141452131     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11700     Document Type: Article

References (43)

1. Bauer KA. Venous thromboembolism in malignancy. J Clin Oncol. 2000;18:3065-3067.
2. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001;102: V215-V224.
3. Sallah S, Ahmad O, Kaiser HE. Pathogenesis of thrombotic disorders in patients with cancer. In Vivo. 2000;14:251-253.
4. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002;87:575-579.
5. Fein DA, Lee WR, Hanlon AL, et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol. 1995;13:2077-2083.
6. Bush RS, Jenkin RD, Allt WE, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer. 1978;37(Suppl):302-306.
7. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86:1528-1536.
8. Adamson J. Erythropoietin, iron metabolism, and red blood cell production. Semin Hematol. 1996;33:5-7.
9. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997;15:1218-1234.
10. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616-1634.
11. Glaspy J. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. Semin Hematol. 1997;34:20-26.
12. Rizzo JD, Seidenfeld J, Piper M, Aronson N, Lichtin A, Littlewood TJ. Erythropoietin: a paradigm for the development of practice guidelines [review]. Hematology (Am Soc Hematol Educ Program). 2001;10-30.
13. Girinski T, Pejovic-Lenfant MH, Bourhis J, et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys. 1989;16:37-42.
14. Churchill DN, Muirhead N, Goldstein M, et al. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol. 1994;4:1809-1813.
15. Singbartl G. Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Invest. 1994;72: S36-S43.
16. De Marchi S, Cecchin E, Falleti E, et al. Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol. 1997;8:1147-1156.
17. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590.
18. Martino MA, Vogel KM, O'Brien SP, Kerstein MD. Erythropoietin therapy improves graft patency with no increased incidence of thrombosis or thrombophlebitis. J Am Coll Surg. 1998;187:616-619.
19. de Andrade JR, Frei D, Guilfoyle M. Integrated analysis of thrombotic/vascular event occurrence in epoetin alfa-treated patients undergoing major, elective orthopedic surgery. Orthopedics. 1999;22:S113-S118.
20. Jilani SM, Glaspy JA. Impact of epoetin alfa in chemotherapy-associated anemia. Semin Oncol. 1998;25:571-576.
21. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
22. Cascinu S, Del Ferro E, Fedeli A, Ligi M, Alessandroni P, Catalano G. Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia. Oncology. 1995;52:422-426.
23. Cascinu S, Fedeli A, Del Ferro E, Luzi FS, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol. 1994;12:1058-1062.
24. Henry DH, Brooks BJ Jr., Case DC Jr., et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am. 1995;1:252.
25. Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol. 2001;19:4126-4134.
26. Case DC Jr., Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst. 1993;85:801-806.
27. Dusenbery KE, McGuire WA, Holt PJ, et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 1994;29:1079-1084.
28. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137-1143.
29. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky Stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-1161.
30. Peters WA III, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606-1613.
31. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in Stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339-1348.
32. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20:966-972.
33. Kurz C, Marth C, Windbichler G, et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol. 1997;65:461-466.
34. Valles J, Santos MT, Aznar J, et al. Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. Blood. 2002;99:3978-3984.
35. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation. 1998;97:350-355.
36. Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation. 1997;95:63-68.
37. Marcus AJ. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Semin Hematol. 1994;31:261-269.
38. Valles J, Santos MT, Aznar J, et al. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood. 1991;78:154-162.
39. Wun T, Paglieroni T, Hammond WP, Kaushansky K, Foster DC. Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro. Am J Hematol. 1997;54:225-232.
40. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95:2983-2989.
41. Diaz-Ricart M, Etebanell E, Cases A, et al. Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Thromb Haemost. 1999;82:1312-1317.
42. Goel MS, Diamond SL. Adhesion of normal erythrocytes at depressed venous shear rates to activated neutrophils, activated platelets, and fibrin polymerized from plasma. Blood. 2002;100:3797-3803.
43. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001;84(Suppl 1):3-10.